Autopsy report · NCT01358708

Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

“Administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 26 participants enrolled.
• Results were posted on the registry 2 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Forest Laboratories

Sponsor type

Industry

Conditions

Diarrhea-predominant Irritable Bowel Syndrome

Interventions

LACTEOL® 340 mg; PLACEBO

Participants

26

Sites

8

Countries

France, Germany

Trials that died the same way

• An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
  “Administrative Reason” (94% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (77% match in meaning)
• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (73% match in meaning)
• IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
  “Business Reasons” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.